{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:23:19Z","timestamp":1772241799975,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Canadian Institutes of Health Research (CIHR) Project Grant","award":["PJT-159782"],"award-info":[{"award-number":["PJT-159782"]}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1T32HD104576"],"award-info":[{"award-number":["1T32HD104576"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40262-024-01447-3","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T19:40:43Z","timestamp":1732563643000},"page":"1735-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-8697","authenticated-orcid":false,"given":"Santosh V.","family":"Suryavanshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0906-7084","authenticated-orcid":false,"given":"Shirley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0365-6613","authenticated-orcid":false,"given":"Dagmar M.","family":"Hajducek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-1797","authenticated-orcid":false,"given":"Abdullah","family":"Hamadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-6376","authenticated-orcid":false,"given":"Cindy H. T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-7408","authenticated-orcid":false,"given":"Patricia D.","family":"Maglalang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-3075","authenticated-orcid":false,"given":"Shinya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8975-5052","authenticated-orcid":false,"given":"Julie","family":"Autmizguine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-5686","authenticated-orcid":false,"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1653","authenticated-orcid":false,"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"1","key":"1447_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cpt.383","volume":"100","author":"S Ito","year":"2016","unstructured":"Ito S. Mother and child: medication use in pregnancy and lactation. Clin Pharmacol Ther. 2016;100(1):8\u201311.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1447_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/cpt.376","volume":"100","author":"S Alwan","year":"2016","unstructured":"Alwan S, Bandoli G, Chambers CD. Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. Clin Pharmacol Ther. 2016;100(1):34\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"1447_CR3","volume-title":"Clinical lactation studies: considerations for study design. Guidance for industry. Draft guidance","author":"U Food","year":"2019","unstructured":"Food U, Administration D. Clinical lactation studies: considerations for study design. Guidance for industry. Draft guidance. Silver Spring: Food and Drug Administration; 2019."},{"issue":"4","key":"1447_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1208\/s12248-021-00599-5","volume":"23","author":"CHT Yeung","year":"2021","unstructured":"Yeung CHT, Ito S, Autmizguine J, Edginton AN. Incorporating breastfeeding-related variability with physiologically based pharmacokinetic modeling to predict infant exposure to maternal medication through breast milk: a workflow applied to lamotrigine. AAPS J. 2021;23(4):70.","journal-title":"AAPS J"},{"issue":"5","key":"1447_CR5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/pharmaceutics15051469","volume":"15","author":"N Nauwelaerts","year":"2023","unstructured":"Nauwelaerts N, Macente J, Deferm N, Bonan RH, Huang MC, Van Neste M, et al. Generic workflow to predict medicine concentrations in human milk using physiologically-based pharmacokinetic (PBPK) modelling\u2014a contribution from the ConcePTION project. Pharmaceutics. 2023;15(5):1469.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1447_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/bdd.2334","volume":"43","author":"A Pansari","year":"2022","unstructured":"Pansari A, Faisal M, Jamei M, Abduljalil K. Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model. Biopharm Drug Dispos. 2022;43(5):201\u201312.","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"1447_CR7","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/bcp.14278","volume":"86","author":"E Weisskopf","year":"2020","unstructured":"Weisskopf E, Guidi M, Fischer CJ, Bickle Graz M, Beaufils E, Nguyen KA, et al. A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: prediction of infant drug exposure through breast milk. Br J Clin Pharmacol. 2020;86(8):1642\u201353.","journal-title":"Br J Clin Pharmacol"},{"key":"1447_CR8","doi-asserted-by":"publisher","first-page":"1167870","DOI":"10.3389\/fpsyt.2023.1167870","volume":"14","author":"A Monfort","year":"2023","unstructured":"Monfort A, Cardoso E, Eap CB, Fischer Fumeaux CJ, Graz MB, Morisod Harari M, et al. Infant exposure to fluvoxamine through placenta and human milk: a case series\u2014a contribution from the ConcePTION project. Front Psychiatry. 2023;14:1167870.","journal-title":"Front Psychiatry."},{"issue":"1","key":"1447_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s44324-023-00001-2","volume":"1","author":"B Chalifour","year":"2023","unstructured":"Chalifour B, Holzhausen EA, Lim JJ, Yeo EN, Shen N, Jones DP, et al. The potential role of early life feeding patterns in shaping the infant fecal metabolome: implications for neurodevelopmental outcomes. NPJ Metab Health Dis. 2023;1(1):2.","journal-title":"NPJ Metab Health Dis."},{"issue":"2","key":"1447_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/mcn.12938","volume":"16","author":"CHT Yeung","year":"2020","unstructured":"Yeung CHT, Fong S, Malik PRV, Edginton AN. Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. Matern Child Nutr. 2020;16(2): e12938.","journal-title":"Matern Child Nutr"},{"issue":"12","key":"1447_CR11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40262-018-0657-2","volume":"57","author":"SR Delaney","year":"2018","unstructured":"Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clin Pharmacokinet. 2018;57(12):1603\u201311.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1447_CR12","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1542\/peds.2005-1417","volume":"117","author":"JC Kent","year":"2006","unstructured":"Kent JC, Mitoulas LR, Cregan MD, Ramsay DT, Doherty DA, Hartmann PE. Volume and frequency of breastfeedings and fat content of breast milk throughout the day. Pediatrics. 2006;117(3):e387\u201395.","journal-title":"Pediatrics"},{"issue":"7","key":"1447_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40262-020-00861-7","volume":"59","author":"P Mian","year":"2020","unstructured":"Mian P, Allegaert K, Conings S, Annaert P, Tibboel D, Pfister M, et al. Integration of placental transfer in a fetal-maternal physiologically based pharmacokinetic model to characterize acetaminophen exposure and metabolic clearance in the fetus. Clin Pharmacokinet. 2020;59(7):911\u201325.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1447_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40262-020-00977-w","volume":"60","author":"XI Liu","year":"2021","unstructured":"Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, et al. Physiologically based pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, dolutegravir, and raltegravir. Clin Pharmacokinet. 2021;60(6):795\u2013809.","journal-title":"Clin Pharmacokinet"},{"issue":"49","key":"1447_CR15","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1016\/j.vaccine.2016.03.040","volume":"34","author":"J Pathirana","year":"2016","unstructured":"Pathirana J, Munoz FM, Abbing-Karahagopian V, Bhat N, Harris T, Kapoor A, et al. Neonatal death: case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(49):6027\u201337.","journal-title":"Vaccine"},{"issue":"2","key":"1447_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","volume":"15","author":"AR Maharaj","year":"2013","unstructured":"Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455\u201364.","journal-title":"AAPS J"},{"issue":"11","key":"1447_CR17","volume":"3","author":"AR Maharaj","year":"2014","unstructured":"Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometr Syst Pharmacol. 2014;3(11): e150.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"1447_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/psp4.12750","volume":"11","author":"J Sinha","year":"2022","unstructured":"Sinha J, Karatza E, Gonzalez D. Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents. CPT Pharmacometr Syst Pharmacol. 2022;11(2):225\u201339.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"6","key":"1447_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40262-024-01367-2","volume":"63","author":"PD Maglalang","year":"2024","unstructured":"Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, et al. Application of physiologically based pharmacokinetic modeling to characterize the effects of age and obesity on the disposition of levetiracetam in the pediatric population. Clin Pharmacokinet. 2024;63(6):885\u201399.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1447_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","volume":"44","author":"R Coupez","year":"2003","unstructured":"Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44(2):171\u20138.","journal-title":"Epilepsia"},{"key":"1447_CR21","unstructured":"Review of environmental assessment for KEPPRA\u00ae oral solution (NDA 021\u2010505). October 31, 2002 ed; 2022."},{"issue":"8\u20139","key":"1447_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","volume":"59","author":"M Strolin Benedetti","year":"2003","unstructured":"Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59(8\u20139):621\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1447_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/cpt.1990","volume":"109","author":"SN Salerno","year":"2021","unstructured":"Salerno SN, Edginton A, Gerhart JG, Laughon MM, Ambalavanan N, Sokol GM, et al. Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants. Clin Pharmacol Ther. 2021;109(1):253\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1447_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/pharmaceutics13030398","volume":"13","author":"I Kacirova","year":"2021","unstructured":"Kacirova I, Grundmann M, Brozmanova H. Umbilical cord, maternal milk, and breastfed infant levetiracetam concentrations monitoring at delivery and during early postpartum period. Pharmaceutics. 2021;13(3):398.","journal-title":"Pharmaceutics"},{"issue":"11","key":"1447_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1447_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40262-023-01345-0","volume":"63","author":"CHT Yeung","year":"2024","unstructured":"Yeung CHT, Autmizguine J, Dalvi P, Denoncourt A, Ito S, Katz P, et al. Maternal ezetimibe concentrations measured in breast milk and its use in breastfeeding infant exposure predictions. Clin Pharmacokinet. 2024;63(3):317\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1447_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s40262-023-01307-6","volume":"62","author":"CHT Yeung","year":"2023","unstructured":"Yeung CHT, Bertrand KA, Best BM, Capparelli E, Chambers CD, Hajducek DM, et al. Cannabidiol exposure through maternal marijuana use: predictions in breastfed infants. Clin Pharmacokinet. 2023;62(11):1611\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1447_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40262-022-01121-6","volume":"61","author":"S Dubinsky","year":"2022","unstructured":"Dubinsky S, Malik P, Hajducek DM, Edginton A. Determining the effects of chronic kidney disease on organic anion transporter1\/3 activity through physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2022;61(7):997\u20131012.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1447_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1528-1167.2005.54804.x","volume":"46","author":"SI Johannessen","year":"2005","unstructured":"Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia. 2005;46(5):775\u20137.","journal-title":"Epilepsia"},{"key":"1447_CR30","unstructured":"Drugs and Lactation Database (LactMed\u00ae). 2006 2022 Nov 30 [cited 2023 July 24]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501229\/."},{"issue":"6","key":"1447_CR31","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","volume":"48","author":"T Tomson","year":"2007","unstructured":"Tomson T, Palm R, Kallen K, Ben-Menachem E, Soderfeldt B, Danielsson B, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48(6):1111\u20136.","journal-title":"Epilepsia"},{"issue":"1","key":"1447_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/bcp.14940","volume":"88","author":"N Dinavitser","year":"2022","unstructured":"Dinavitser N, Kohn E, Berlin M, Brandriss N, Bar-Chaim A, Keidar R, et al. Levetiracetam in lactation: how much is excreted into human breast milk? Br J Clin Pharmacol. 2022;88(1):199\u2013205.","journal-title":"Br J Clin Pharmacol"},{"key":"1447_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.reprotox.2016.03.032","volume":"60","author":"E Kohn","year":"2016","unstructured":"Kohn E, Brandriss N, Soback S, Bar-Haim A, Berkovitch M. Levetiracetam and lamotrigine excretion in breast milk. Reprod Toxicol. 2016;60:184.","journal-title":"Reprod Toxicol"},{"key":"1447_CR34","unstructured":"UCB Pharma Inc. NDA 21-035 KEPPRA (levetiracetam). 1999. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21035_Keppra_Approv.pdf."},{"issue":"1","key":"1447_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1331\/JAPhA.2012.10139","volume":"52","author":"FJ Nice","year":"2012","unstructured":"Nice FJ, Luo AC. Medications and breast-feeding: current concepts. J Am Pharm Assoc (2003). 2012;52(1):86\u201394.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"1447_CR36","unstructured":"Hallare J. Half life. In: StatPearls. Treasure Island: StatPearls Publishing; 2023."},{"issue":"6","key":"1447_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","volume":"48","author":"TA Glauser","year":"2007","unstructured":"Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48(6):1117\u201322.","journal-title":"Epilepsia"},{"issue":"6","key":"1447_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/15563659409017975","volume":"32","author":"A de Peyster","year":"1994","unstructured":"de Peyster A, Willis WO, Liebhaber M. Cholinesterase activity in pregnant women and newborns. J Toxicol Clin Toxicol. 1994;32(6):683\u201396.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"181","key":"1447_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106349","volume":"1","author":"J Chen","year":"2023","unstructured":"Chen J, You X, Wu W, Guo G, Lin R, Ke M, et al. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy. Eur J Pharm Sci. 2023;1(181): 106349.","journal-title":"Eur J Pharm Sci"},{"key":"1447_CR40","first-page":"6527458","volume":"2016","author":"S Almas","year":"2016","unstructured":"Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. Multiple Scler Int. 2016;2016:6527458.","journal-title":"Multiple Scler Int"},{"key":"1447_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reprotox.2015.07.068","volume":"57","author":"P Ylikotila","year":"2015","unstructured":"Ylikotila P, Ketola RA, Timonen S, Malm H, Ruuskanen JO. Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. Reprod Toxicol. 2015;57:204\u20136.","journal-title":"Reprod Toxicol"},{"key":"1447_CR42","unstructured":"Kramer G, Hosli, I, Glanzmann, R, Holzgreve, W. Levetiracetam accumulation in human breast milk. American Epilepsy Society. Seattle: Epilepsia; 2002. p. 105."},{"issue":"4","key":"1447_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1212\/WNL.0b013e3182088297","volume":"76","author":"R Shallcross","year":"2011","unstructured":"Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011;76(4):383\u20139.","journal-title":"Neurology"},{"issue":"10","key":"1447_CR44","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1111\/bcp.14538","volume":"88","author":"RHJ Verstegen","year":"2022","unstructured":"Verstegen RHJ, Anderson PO, Ito S. Infant drug exposure via breast milk. Br J Clin Pharmacol. 2022;88(10):4311\u201327.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01447-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:10:58Z","timestamp":1734358258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1447"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01447-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"23 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by the Canadian Institutes of Health Research (CIHR) Project Grant PJT-159782. PDM receives support from the Eunice Kennedy Shriver NICHD of the National Institutes of Health (NIH) under Award Number 1T32HD104576. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All data used in the model development and evaluation can be found in the referenced works in Tables  and .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The original studies that took part in collecting levetiracetam data were approved by institutional review boards. No new enrollments of subjects took place for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to participate informed consent and assent, if applicable, were obtained from all participants of the original studies that took part in collecting the levetiracetam data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The open-source platforms by Open Systems Pharmacology, PK-Sim\u00ae and Mobi\u00ae were used.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SVS: conceptualization, data acquisition, data analyses, interpretation of the results, and drafting of the manuscript. SW: conceptualization, methodology, data analyses, interpretation of the results, high-quality figures, and drafting of the manuscript. DMH: methodology, data analysis, high-quality figures, and critical revision of the manuscript. AH: scripting. CHTY: conceptualization, methodology, and interpretation of the results. PM: methodology, data acquisition, and critical revision of the manuscript. SI, JA, and DG: supervision and critical revision of the manuscript. ANE: conceptualization, supervision, critical revisions of the manuscript. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}